Comparable stake leader
FMR LLC
SEC ownership of REPLIGEN CORP
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000730272.
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
30 Sep 2026
- Public ticker
- RGEN on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000730272
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of REPLIGEN CORP (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
30 Sep 2026
13D/G
13F
Lead comparable stake: 13%
44 rows are not safely comparable across share classes.
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 13%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
13%
BlackRock, Inc.
9.3%
VANGUARD CAPITAL MANAGEMENT LLC
5%
Roy T. Eddleman
4.8%
Roy T. Eddleman Living Trust
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
|
13%
Reported 13D/G
· 30 Sep 2026
|
$1,415,066,128
7,361,318 shares
|
+$859,302,317 | 30 Sep 2026 |
| BlackRock, Inc. |
13D/G
|
9.3%
Reported 13D/G
· 31 Mar 2025
|
$724,772,059
5,198,107 shares
|
$0 | 31 Mar 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
5%
Reported 13D/G
· 30 Jun 2026
|
$469,568,102
2,442,741 shares
|
— | 30 Sep 2026 |
| Roy T. Eddleman |
13D/G
Roy T. Eddleman Living Trust
|
4.8%
Reported 13D/G
· 31 Dec 2024
|
$377,254,217
2,705,689 shares
|
$0 | 31 Dec 2024 |
| Roy T. Eddleman Living Trust |
13D/G
|
4.8%
Reported 13D/G
· 31 Dec 2025
|
$443,354,200
2,705,689 shares
|
$0 | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
T. Rowe Price Associates, Inc.
|
3.1%
Reported 13D/G
· 30 Jun 2026
|
$253,813,389
1,751,887 shares
|
-$412,614,328 | 30 Jun 2026 |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC |
13F
Company
|
—
denominator unverified
|
$536,329,005
2,790,038 shares
|
— | 30 Sep 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$436,722,147
2,271,873 shares
|
— | 30 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$8,248,071.
Buys
$0
Insiders: 0
Sells
$8,248,071
Insiders: 4
Net
-$8,248,071
Shares: -46,970
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 46,970
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 32,368 | $0 | $5,953,260 | -$5,953,260 |
| 3-6 | 0 | 1,263 | $0 | $185,785 | -$185,785 |
| 6-9 | 0 | 3,832 | $0 | $536,480 | -$536,480 |
| 9-12 | 0 | 9,507 | $0 | $1,572,546 | -$1,572,546 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to REPLIGEN CORP. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Anthony Hunt
Net 12M change
-$8.25M
Full value: -$8,248,071 · USD · 12-month changeLatest report
06 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anthony Hunt | Director | $11,130,078 | Mixed | 02 Mar 2026 | ||
| Karen A. Dawes | Director | $10,935,581 | -$44,275 | -0.4% | Mixed | 14 May 2026 |
| Olivier Loeillot | Chief Executive Officer, Director | $8,699,720 | -$7,686,710 | -47% | Filing P/S | 05 Oct 2026 |
| Jon Snodgres | Chief Financial Officer | $5,499,867 | Mixed | 16 May 2023 | ||
| Glenn P. Muir | Director | $4,718,808 | Mixed | 14 May 2026 | ||
| Christine Gebski | SVP, Filtration & Chromatography | $4,478,619 | Mixed | 14 May 2024 | ||
| James Bylund | Chief Operating Officer | $3,488,544 | -$331,301 | -8.7% | Mixed | 05 Mar 2026 |
| Ralf Kuriyel | Senior VP, R&D | $2,752,907 | Mixed | 05 Mar 2026 | ||
| Jason K. Garland | Cfo | $2,511,587 | -$185,785 | -6.9% | Mixed | 25 Sep 2026 |
| Brian Robb Douglass | Chief Product Officer | $1,669,517 | Median | 06 Oct 2026 | ||
| Martin D. Madaus | Director | $988,745 | Mixed | 14 May 2026 | ||
| Violetta Hughes | Chief Accounting Officer | $863,801 | Mixed | 05 Mar 2026 | ||
| Manner Carrie Eglinton | Director | $643,415 | Mixed | 14 May 2026 | ||
| Nicolas Barthelemy | Director | $640,469 | Mixed | 14 May 2026 | ||
| Rohin Mhatre | Director | $590,749 | Mixed | 14 May 2026 | ||
| Konstantin Konstantinov | Director | $458,201 | Mixed | 14 May 2026 | ||
| Margaret Pax | Director | $354,756 | Mixed | 14 May 2026 | ||
| Thomas F. Ryan Jr. | Director | $214,368 | Mixed | 01 Mar 2022 |
Recent insider transactions for REPLIGEN CORP
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Brian Robb Douglass | RGEN | Common Stock | Award | 8.77% | 700 | 8,685 | 06 Oct 2026 | Direct | ||
| Brian Robb Douglass | RGEN | Stock Option (Right to Buy) | Award | 675 | 675 | 06 Oct 2026 | Direct | |||
| Olivier Loeillot | RGEN | Common Stock | Options Exercise | 9.18% | 4,202 | 49,990 | 05 Oct 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -10.8% | -$1,036,654 | $187.29 | -5,535 | 45,788 | 05 Oct 2026 | Direct |
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Options Exercise | -33.3% | -4,202 | 8,405 | 05 Oct 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -2.58% | -1,248 | 47,121 | 02 Oct 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Tax liability | -2.24% | -421 | 18,408 | 25 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -21.1% | -$2,459,740 | $190.00 | -12,946 | 48,369 | 24 Sep 2026 | Direct |
| Olivier Loeillot | RGEN | Common Stock | Options Exercise | 29.5% | 12,946 | 56,773 | 24 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Options Exercise | -58.8% | -12,946 | 9,085 | 24 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -10.1% | -$976,680 | $180.00 | -5,426 | 48,369 | 21 Sep 2026 | Direct |
| Olivier Loeillot | RGEN | Common Stock | Options Exercise | 11.2% | 5,426 | 53,795 | 21 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Options Exercise | -50% | -5,426 | 5,426 | 21 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -5.9% | -$503,506 | $165.90 | -3,035 | 48,369 | 04 Sep 2026 | Direct |
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -5.24% | -2,842 | 51,404 | 03 Sep 2026 | Direct | ||
| Violetta Hughes | RGEN | Common Stock | Tax liability | -4.19% | -277 | 6,331 | 01 Sep 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -9.09% | -$976,680 | $180.00 | -5,426 | 54,246 | 20 Aug 2026 | Direct |
| Olivier Loeillot | RGEN | Common Stock | Options Exercise | 10% | 5,426 | 59,672 | 20 Aug 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Options Exercise | -33.3% | -5,426 | 10,852 | 20 Aug 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Sale | -2.74% | -$79,500 | $150.00 | -530 | 18,829 | 16 Jul 2026 | Direct |
| Jason K. Garland | RGEN | Common Stock | Sale | -3.65% | -$106,285 | $145.00 | -733 | 19,359 | 25 Jun 2026 | Direct |
| Martin D. Madaus | RGEN | Common Stock | Award | 17.8% | 995 | 6,581 | 14 May 2026 | Direct | ||
| Martin D. Madaus | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Konstantin Konstantinov | RGEN | Common Stock | Award | 34.4% | 995 | 3,889 | 14 May 2026 | Direct | ||
| Konstantin Konstantinov | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Manner Carrie Eglinton | RGEN | Common Stock | Award | 22.3% | 995 | 5,461 | 14 May 2026 | Direct | ||
| Manner Carrie Eglinton | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Rohin Mhatre | RGEN | Common Stock | Award | 24.8% | 995 | 5,014 | 14 May 2026 | Direct | ||
| Rohin Mhatre | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Margaret Pax | RGEN | Common Stock | Award | 49.4% | 995 | 3,011 | 14 May 2026 | Direct | ||
| Margaret Pax | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Award | 2.55% | 995 | 40,051 | 14 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Karen A. Dawes | RGEN | Common Stock | Award | 1.08% | 995 | 92,816 | 14 May 2026 | Direct | ||
| Karen A. Dawes | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Nicolas Barthelemy | RGEN | Common Stock | Award | 22.4% | 995 | 5,436 | 14 May 2026 | Direct | ||
| Nicolas Barthelemy | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Options Exercise | 6.65% | 2,434 | 39,056 | 07 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Options Exercise | 2,434 | 2,434 | 07 May 2026 | Direct | |||
| Brian Robb Douglass | RGEN | Common Stock | Tax liability | -4.01% | -334 | 7,985 | 07 May 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -6.6% | -$536,480 | $140.00 | -3,832 | 54,246 | 21 Apr 2026 | Direct |
| Violetta Hughes | RGEN | Common Stock | Award | 59.5% | 2,466 | 6,608 | 05 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Award | 35.8% | 5,284 | 20,062 | 05 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Stock Option (Right to Buy) | Award | 5,669 | 5,669 | 05 Mar 2026 | Direct | |||
| Olivier Loeillot | RGEN | Common Stock | Award | 71.1% | 24,134 | 58,078 | 05 Mar 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Award | 25,890 | 25,890 | 05 Mar 2026 | Direct | |||
| James Bylund | RGEN | Common Stock | Award | 43.9% | 7,751 | 25,423 | 05 Mar 2026 | Direct | ||
| James Bylund | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct | |||
| Jason K. Garland | RGEN | Common Stock | Award | 62.8% | 7,751 | 20,092 | 05 Mar 2026 | Direct | ||
| Jason K. Garland | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.